Navigation Links
Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
Date:3/22/2013

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088. The USPTO granted claims covering the novel small molecule EZH2 inhibitor EPZ-6438 (E7438), a drug candidate for a genetically defined type of non-Hodgkin lymphomas. The patent issuance marks Epizyme's first claims covering this chemical matter.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In March 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an option to co-commercialize, co-develop and share profits for this program with Eisai in the United States.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit http://www.epizyme.com.


'/>"/>
SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 Although ... of the first transcriptome-wide analyses appearing around 2008, ... assay for RNA measurement. In the last several ... more specific, work with smaller input amounts, process ... (eg, blood samples). On the bioinformatics side, there ...
(Date:7/31/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, August 7, 2014, and that the ... at 4:30 p.m. ET that afternoon. Management will provide ...
(Date:7/31/2014)... 31, 2014 The Kidney Cancer Association (KCA) ... monthly news magazine, Kidney Cancer News. , Bill Bro, ... a website maintained by an international news organization. When we ... in viewers.” , This month’s program highlights news of an ... analyzed in a recent study. Kidney Cancer News also presents ...
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... Elekta, a world leader in clinical,solutions for ... are utilizing Elekta technology to implement clinical treatments ... CE designation of,VMAT in Europe, the way has ... UK and General Hospital Vienna in Austria to ...
... Calif., Jan. 18 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... it has held a meeting at the ... Company,s Distribution Network. Attendees included,representatives from local ... large volume agricultural products dealers., In ...
... Corporation plc,(NASDAQ: AMRND ) today announced that, at ... for 10 reverse split of each of its Ordinary,Shares. ... of business,yesterday, January 17, 2008., Thomas Lynch, Amarin ... to report that over 95% of the votes cast ...
Cached Biology Technology:Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 2Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 3Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network 2Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network 3Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 2Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 3Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 4Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 5Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 6Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 7Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 8Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 9
(Date:7/31/2014)... A Florida State University researcher found that bacteria in ... components of the oil released during the Deepwater Horizon ... the most toxic contaminants. , In two new studies ... Mason found a species of bacteria called Colwellia ... ethylbenzene and xylene compounds that were released as part ...
(Date:7/31/2014)... nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine ... online publications, British Medical Journal Open (BMJ Open) ... BMJ Open article looked at the effects ... showed that tree nut consumption resulted in a significant ... PLOS ONE article focused on the effect of ...
(Date:7/30/2014)... Society (ACS) announced today that David L. Kaplan, Ph.D., ... Science & Engineering as editor-in-chief. With the first ... journal will feature high-quality research in the rapidly burgeoning ... derived materials that interact with living or biological systems. ... the tremendous growth in the field of biomaterials over ...
Breaking Biology News(10 mins):New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... LUMPUR, Malaysia, Oct. 17, 2012 Rising crime ... governments to increase monitoring and introduce reliable border ... aimed at criminal identification and automated immigration at ... drive biometrics adoption in the government vertical across ...
... 2012  Aware, Inc. (NASDAQ: AWRE ), a ... products, today reported financial results for its third quarter ... DSL service assurance hardware business have been reported as ... shutdown of that business during the third quarter. Accordingly, ...
... Adm. Matthew Klunder, the chief of naval research, told a ... and technology (S&T) conference this week that he intends to ... together on a quarterly basis, starting in 2013, to accelerate ... every two years, which is phenomenal and very valuableand probably ...
Cached Biology News:Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6In an uncertain world, Navy needs science and technology collaboration, chief says 2
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mus musculus MARCKS-like protein, mRNA...
Biology Products: